Status:
RECRUITING
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Hepatocellular Carcinoma
Immunotherapy
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Through a retrospective study of patients who underwent comprehensive treatment for hepatocellular carcinoma at the Second Affiliated Hospital of Zhejiang University, we explored the risk factors rela...
Detailed Description
As of 2020, hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related deaths, making it one of the world's major public health issues. The incidence of HCC is increasing year by year...
Eligibility Criteria
Inclusion
- Patients with advanced hepatocellular carcinoma
Exclusion
- Have comorbidities of severe diabetes, heart failure, liver and/or kidney failure
- Have a history of schizophrenia
- Have a history of other malignant tumors or metastatic liver tumors discovered after surgery
- Received anti-tumor drugs for other diseases
- Special groups such as pregnant and lactating women.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06542796
Start Date
September 1 2024
End Date
May 1 2027
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2ndAffiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009